Registrants can access abstracts by title or number using the AAIC Mobile App

1. A HABLE Study of the Relationship of Blood-based Biomarkers of AD and Cognition Functioning in Cognitively Normal: The Impact of Ethnicity

Abstract ID: 55280

2. A new blood-based biomarker of Aβ clearance – the monocyte Aβ mid-domain assay

Abstract ID: 56346

3. A panel of novel astrocytic and synaptic biomarkers in serum and CSF for the differential diagnosis of Frontotemporal dementia

Abstract ID: 51338

4. Alterations in white matter integrity in cognitively stable Down syndrome correlate with plasma neurofilament light chain; evidence of early myelin breakdown.

Abstract ID: 56379

5. Assessment of AD Related Plasma Biomarkers in Diverse Ancestral Populations

Abstract ID: 56258

6. Association of Plasma neurofilament light with Cognition, Cortical atrophy, Amyloid and Tau PET in cognitive impaired patients

Abstract ID: 55915

7. Association of deep-learning-derived brain computed tomography measures with cognition and blood-based biomarkers of neurodegenerative diseases

Abstract ID: 55910

8. Associations of fully automated Elecsys CSF and novel plasma biomarkers with Alzheimer’s disease neuropathology

Abstract ID: 53735

9. Associations of plasma neurofilament light protein levels with cognitive functions and brain structure parameters

Abstract ID: 55922

10. Associations of smoking and biohazard exposure with Alzheimer’s Disease brain and plasma biomarkers in early old age.

Abstract ID: 56627

11. Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status in amnestic-MCI patients

Abstract ID: 57231

12. Blood Markers of Neuronal/Axonal and Glial Injury for Clinical Progression in a Predominately Hispanic Cohort: the Texas Alzheimer’s Research and Care Consortium

Abstract ID: 54270

13. Brain Atrophy and White Matter Hyperintensities are Independently Associated with Plasma Neurofilament Light Chain in an Asian Cohort of Patients with Mixed Pathology

Abstract ID: 52868


Abstract ID: 56218

15. CSF Aβ42 and Aβ40 and their relation to brain soluble and insoluble Aβ in the 5xFAD mouse model of Alzheimer’s disease

Abstract ID: 55684

16. CSF SNAP-25 dynamics in healthy aging and across the spectrum of Alzheimer’s Disease

Abstract ID: 57662

17. Clinical and analytical comparison of three assays for plasma P-tau isoforms on an ultrasensitive platform

Abstract ID: 54044

18. Comparison of Plasma and CSF Biomarkers Across Ethnoracial Groups in ADNI

Abstract ID: 56590

19. Data-driven approach for early detection of pathological pathways in middle-aged adults with family history of sporadic Alzheimer’s disease

Abstract ID: 57768

20. Development and Validation of a High Sensitivity Assay for Measuring p217+tau in Plasma

Abstract ID: 54406

21. Development and analytical characterization of novel tau Simoa assays targeting full-length tau in CSF and mid-tau in CSF and plasma

Abstract ID: 54911

22. Diagnostic accuracy of the monocyte Aβ mid-domain assay for CSF determined brain amyloid deposition.

Abstract ID: 56435

23. Differential cognitive correlates of tau and neurofilament light chain in cerebrospinal fluid of frontotemporal lobar degeneration patients with and without Alzheimer’s markers

Abstract ID: 56446

24. Distinctive effect of biological sex in AD-related CSF and plasma biomarkers

Abstract ID: 52959

25. Evaluation of Class C CpG ODN Efficacy and Safety Profile in a Squirrel Monkey Model of AD Pathology.

Abstract ID: 55028

26. Factors associated with levels of plasma markers of amyloid pathology and neurodegeneration in a population-based sample

Abstract ID: 51720

27. Granulocyte-Macrophage Colony-Stimulating Factor Reverses Alzheimer’s Disease Pathology in the TgF344-AD Rat Model

Abstract ID: 56289

28. Interaction of Obstructive Sleep Apnea Severity and amyloid burden on novel plasma biomarkers of Tau and neurofilament light protein in community-dwelling cognitively normal older-adults

Abstract ID: 55491

29. Levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin are selectively increased in the cerebrospinal fluid of patients with Alzheimer’s Disease

Abstract ID: 56339

30. Longitudinal characterization of mild cognitive impairment and dementia in World Trade Center responders at midlife

Abstract ID: 55823

31. Longitudinal plasma Alzheimer’s disease biomarkers in an Alzheimer’s Disease Research Center cohort suggest pTau181 as the most reliable plasma biomarker for brain Alzheimer’s pathology.

Abstract ID: 55953


Abstract ID: 55985

33.Neuropsychological correlates of plasma NfL in adults with Down syndrome

Abstract ID: 52881

34. Plasma biomarkers of neurodegeneration and neuroinflammantion in hospitalized COVID-19 patients with and without new neurological symptoms

Available July 29, 2021 at 1:00 pm MDT

35.Plasma P-tau181 and NfL are central nodes in a network of diagnostic, biomarker, and demographic data.

Abstract ID: 52669

36. Plasma P-tau181 levels predict amyloid pathology in cognitively unimpaired individuals after 10 years

Abstract ID: 51727

37. Plasma and CSF biomarkers for Alzheimer’s Disease Among Caribbean Hispanics

Abstract ID: 57653

38. Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients

Abstract ID: 55520

39. Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer’s disease

Abstract ID: 50187

40. Plasma glial fibrillary acidic protein is an early and specific marker of amyloid-β pathology in Alzheimer’s disease

Abstract ID: 55538

41. Plasma neurofilament light chain (NfL) relates to preclinical changes in cognition, structural white matter integrity and markers of cerebral small-vessel disease: a population-based study

Abstract ID: 53611

42. Plasma p-tau231 in the Alzheimer’s disease continuum: a multi-cohort evaluation of diagnostic performance, detection of Aβ pathology and preclinical application

Abstract ID: 56186

43. Plasma p217+tau concordance with 18F-NAV4694 beta-amyloid and 18F-MK6240 tau PET in mild Alzheimer’s disease and cognitively unimpaired participants in the AIBL/ADNeT cohort.

Abstract ID: 55706

44. Plasma pTau isoform assessment across disease stages

Abstract ID: 50710

45. Pre-analytical and clinical validation on the highway to implementation of novel dementia blood tests

Abstract ID: 50709


Abstract ID: 56329

47. Racial differences in plasma and CSF AD biomarkers show lower p-tau181 in African Americans compared to Whites

Abstract ID: 56514

48. SavaDx, a novel plasma biomarker to detect Alzheimer’s disease, confirms mechanism of action of simufilam

Abstract ID: 54385

49. Sex differences in levels of plasma neurofilament light and total tau in adults with Down Syndrome

Abstract ID: 55785

50. Stability of the novel blood-based biomarkers under pre-analytical sample handling conditions: results of the SABB-GBSC working group.

Abstract ID: 55441

51. Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer’s continuum

Abstract ID: 55448

52. The NeuroMET project: Metrology and innovation for early diagnosis and accurate stratification of patients with neurodegenerative diseases

Abstract ID: 53655

53. The association between plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light and clinical AD risk: results from prospective cohort study followed over 17 years

Abstract ID: 57547


The impact of cerebrovascular disease on blood-based biomarkers of Alzheimer’s disease

Abstract ID: 55434

55. Utility of Combined Plasma Amyloid Beta 40, Amyloid Beta 42, Total Tau, and NfL along with a Measure of Cognitive Functioning in Detecting Cognitive Impairment among Hispanic, Mexican Americans Compared to Non-Hispanic Whites

Abstract ID: 56344

56. Utility of Total Tau as a Biomarker for Alzheimer’s Disease among adults with Down Syndrome

Abstract ID: 52886

57. Vascular and Inflammatory Plasma Biomarkers Correlate with Human Post-Mortem Cerebral Vascular Pathology

Abstract ID: 52379

58. Baseline plasma total tau predicts longitudinal cognitive and functional decline in aging adults

Abstract ID: 55665

59. Plasma biomarker profiles and the association with cognitive function across the clinical spectrum of Alzheimer’s disease

Abstract ID: 52167

60. Matrix Metalloproteinase-10 as a novel biomarker of neurodegeneration in Alzheimer’s disease

Abstract ID: 56323

61. Stability of blood-based biomarkers of cognitive impairment

Abstract ID: 52733

62. A Comparison of Multiple Platforms for Quantifying ATN Values in Cerebrospinal Fluid

Abstract ID: 56321

63. Association of tau pathology and vascular risk factor burden with longitudinal measures of plasma neurofilament light

Abstract ID: 56631

64. Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early AD

Abstract ID: 56164

65. A multimodal study on the effect of sex on Alzheimer’s disease clinical and biomarker changes in adults with Down syndrome

Abstract ID: 55499

66. Biomarker driven enrichment strategies for tau pathology in AD clinical trials

Abstract ID: 55656

67. Blood phosphorylated tau 181 predicts early, preclinical brain amyloid deposition

Abstract ID: 55485

68. CSF amyloid-beta, tau, neurodegenerative, and inflammatory biomarkers in cognitively unimpaired late middle-aged & older adult APOE ε4 homozygotes, heterozygotes, & non-carriers from the Arizona APOE Cohort

Abstract ID: 57242

69. Comparison of the prognostic value of cerebrospinal fluid and plasma neurofilament light in predicting longitudinal decline in white matter integrity among older adults

Abstract ID: 54958

70. Complement and NfL associations with brain structure and functional connectivity alterations in presymptomatic and symptomatic GRN mutation carriers

Abstract ID: 50737

71. Creatinine and body mass index influence on plasma amyloid ratio, p-tau217 and neurofilament light

Abstract ID: 57769

72. Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers

Abstract ID: 52117

73. Disease progression models of familial frontotemporal lobar degeneration and the temporal ordering of biomarker changes in an international cohort

Abstract ID: 55353

74. From brain volumes to subgroup classification in genetic mutation carriers for frontotemporal dementia: a cluster analysis in the GENFI study

Abstract ID: 52189

75. Individualized diagnostic and prognostic blood-based models for use in clinical practice and trials

Abstract ID: 50712

76. Longitudinal changes of phosphorylated tau 181 and neurofilament light chain in plasma and their associations with tau- and amyloid-PET

Abstract ID: 52940

77. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up

Abstract ID: 57889

78. Plasma NfL trajectory during ICU-treatment of COVID-19 patients – a prospective cohort study

Abstract ID: 57841

79. Plasma and cerebrospinal fluid neurofilament light protein concentrations are differentially associated with biomarker evidence of neurodegeneration in a community-based population of 70-year olds

Abstract ID: 53565

80. Plasma biomarkers of Alzheimer’s disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly

Abstract ID: 52909

81. Plasma biomarkers predict longitudinal amyloid accumulation, tau burden, brain atrophy and cognitive decline in early Alzheimer’s disease

Abstract ID: 55597

82. Plasma neurofilament light predicted future declines in cognition and function in Alzheimer’s disease in the FIT-AD Trial

Abstract ID: 51891

83. Role of plasma ptau181, neurofilament light, and subjective cognitive decline in predicting progression to MCI in older adults from the Alzheimer’s Disease Neuroimaging Initiative

Abstract ID: 52497

84. Serum immunoglobulins and biomarkers of dementia: a population-based study

Abstract ID: 54512

85. Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer’s disease

Abstract ID: 55011

86. Subacute plasma neurofilament light predicts neurodegeneration after moderate-severe traumatic brain injury

Abstract ID: 52522

87. The association between retinal neurodegeneration and plasma neurofilament light chain: a population-based study

Abstract ID: 51389

88. Clustering Biomarkers in Dominantly Inherited Alzheimer’s Disease

Abstract ID: 52149

89. How to define ‘N’ in the ATN classification in subjective cognitive decline: the SCIENCe project

Abstract ID: 55891